Nephrology
Latest news
146 articles · 20 / page
Interleukin-6 Inhibition: A New Frontier in Reducing Residual Cardiovascular and Renal Risk
Recent clinical evidence identifies Interleukin-6 (IL-6) as a critical driver of cardiovascular events. The ZEUS trial and recent LoDoCo2 analyses suggest that targeting IL-6 with ziltivekimab may significantly reduce risk for patients with
Protecting Your Kidneys and the Planet: The Impact of the Planetary Health Diet on Chronic Kidney Disease
A large-scale study using UK Biobank data reveals that adhering to a Planetary Health Diet significantly lowers the risk of chronic kidney disease, emphasizing the dual benefits of plant-forward, sustainable eating for both personal health
Adherence to the Planetary Health Diet Linked to Significantly Lower Risk of Chronic Kidney Disease, with Stronger Benefits for Women
A large-scale multi-cohort study involving nearly 190,000 participants reveals that the EAT-Lancet reference diet, measured by the Planetary Health Diet Index, reduces the risk of incident chronic kidney disease, particularly among women, a
Saving the Planet, One Kidney at a Time: The Power of the Planetary Health Diet
Recent research from the UK Biobank reveals that a sustainable, plant-forward diet can lower chronic kidney disease risk by 26%, offering a dual solution for environmental and personal health.
Finerenone Reduces Albuminuria via Hemodynamic Mechanisms Rather Than Improving Arterial Stiffness: Insights from the FIVE-STAR Trial
The FIVE-STAR trial demonstrates that while finerenone significantly reduces albuminuria in patients with T2D and CKD, it does not improve arterial stiffness (CAVI). These findings suggest that its cardiorenal benefits are primarily driven
Beyond the Arteries: Why Finerenone is a Game-Changer for Diabetic Kidney Disease
The FIVE-STAR trial reveals that finerenone’s cardiorenal benefits stem from reducing internal kidney pressure rather than improving arterial stiffness, offering a new perspective on managing type 2 diabetes and chronic kidney disease.
Culturally Tailored Community Health Worker Support Mitigates Interdialytic Weight Gain in Hispanic and Latino Hemodialysis Patients
The Navigate-Kidney trial demonstrates that community health worker support significantly improves interdialytic weight gain, dialysis adherence, and patient activation among Hispanic and Latino individuals on hemodialysis, addressing criti
A New Frontier in Fabry Cardiomyopathy: Validating a T1-Inclusive Prognostic Score for Cardiovascular Risk
This article explores a novel 3-year prognostic score for Fabry Disease cardiomyopathy, integrating CMR-derived T1 values, LV mass, and LGE extent to predict adverse events, emphasizing the negative predictive value of normal T1 mapping.
Higher Hospital-Level Utilization of Continuous Kidney Replacement Therapy Associated with Reduced Mortality in Critically Ill Patients
A large-scale multicenter study reveals that hospitals with higher utilization rates of continuous kidney replacement therapy (CKRT) achieve significantly lower 90-day mortality for critically ill AKI patients compared to low-utilization ce
Severe Acute Kidney Injury Survivors in India and Southeast Asia Face Staggering Rates of Long-Term Adverse Events
A large-scale multicenter study reveals that 46.6% of severe AKI survivors in India and Southeast Asia experience major adverse kidney events (MAKE) within two years, with mortality and new-onset chronic kidney disease being the primary dri
Beyond eGFR and UACR: kidneyintelX.dkd Refines Risk Stratification and Monitors Treatment Response in Diabetic Kidney Disease
A post-hoc analysis of the CANVAS and CREDENCE trials reveals that the kidneyintelX.dkd score significantly improves risk reclassification and monitors the therapeutic impact of canagliflozin in patients with type 2 diabetes and chronic kid
Kidney Replacement Therapy Independently Predicts 90-Day Mortality in Critically Ill Patients with Obesity: A 15-Year Trend Analysis
A 15-year cohort study reveals that obese ICU patients requiring kidney replacement therapy face nearly triple the mortality rate of those who do not, despite a declining trend in overall acute kidney injury incidence within this high-risk
Post-Heart Transplantation Survival Comes with a Heavy Cardiovascular-Kidney-Metabolic Burden: New Data on DM2 and CKD Risks
A longitudinal study of 944 heart transplant recipients reveals a staggering incidence of metabolic and renal dysfunction. While diabetes significantly increases mortality risk, the study highlights the potential of SGLT2 inhibitors and GLP
Optimizing Acid-Base Stability in CVVH: Why Lower Bicarbonate Fluids Outperform Standard Concentrations During Regional Citrate Anticoagulation
This randomized controlled trial demonstrates that a lower bicarbonate replacement fluid (22 mmol/l) provides superior acid-base stability compared to a higher concentration (30 mmol/l) during CVVH with citrate anticoagulation, significantl
Empagliflozin Enhances Cardiovascular Protection in HFrEF Patients with Low Serum Magnesium: Evidence from EMPEROR-Reduced
This analysis of the EMPEROR-Reduced trial demonstrates that empagliflozin increases serum magnesium levels and provides a more pronounced reduction in cardiovascular events for patients with low baseline magnesium, revealing a novel electr
Conservative Kidney Management Versus Dialysis in Older Adults with Kidney Failure: Evidence Is Inconclusive — What Clinicians Should Know
A 2025 Cochrane review of 24 non-randomised studies (26,127 participants) found very low‑certainty evidence comparing conservative kidney management (CKM) with dialysis in people aged ≥65 with stage 5 chronic kidney disease; survival and qu
Hospital Acute Kidney Injury Strongly Linked to Long-Term Death, Dialysis, and CKD: Meta-Analysis of Matched-Control Studies
A meta-analysis of 14 matched-control studies (n=1,058,109) finds that survivors of in-hospital AKI face higher long-term mortality, greater subsequent dialysis need, and elevated risk of CKD versus matched controls.
Lorundrostat Lowers 24‑Hour Systolic Blood Pressure in Treatment‑Resistant Hypertension but Raises Hyperkalemia Concerns
A randomized, placebo‑controlled trial found lorundrostat reduced 24‑hour systolic BP by ~7–8 mm Hg versus placebo in patients with uncontrolled, treatment‑resistant hypertension; notable rates of marked hyperkalemia occurred only in active
Pegcetacoplan Markedly Reduces Proteinuria in C3 Glomerulopathy and Immune‑Complex MPGN: Results from the VALIANT Phase 3 Trial
In the phase 3 VALIANT trial, pegcetacoplan, a C3/C3b inhibitor, produced a large, rapid reduction in proteinuria versus placebo at 26 weeks in patients with C3 glomerulopathy or primary immune‑complex MPGN, with an acceptable short-term sa
Comprehensive Summary of the FINEARTS-HF Trial Results on Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
The FINEARTS-HF trial demonstrates finerenone’s efficacy and safety in reducing heart failure events, improving symptoms, and lowering new-onset diabetes risk, with consistent benefits across sex, ejection fraction ranges, frailty levels, a
Browse by specialty
Open language-specific specialty feeds and department pages.